Viridian Q1 FY26 net loss widens to $104.9 million; revenue rises to $141,000

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.

VRDN

0.00
  • Viridian Therapeutics posted a wider net loss of $104.9 million, versus $86.9 million a year earlier.
  • Revenue rose to $141,000 from $72,000.
  • R&D expenses edged up to $77.6 million from $76.8 million.
  • SG&A expenses more than doubled to $38.7 million from $17.1 million, due to preparatory commercial activities for veligrotug, including higher personnel-related costs from headcount increases.
  • Cash, cash equivalents, and marketable securities fell to $762.2 million as of March 31, 2026, from $874.7 million at end-2025; veligrotug faces an FDA PDUFA target action date of June 30, 2026 with launch preparations completed, while Viridian plans to submit an elegrobart BLA in Q1 2027 after positive REVEAL-1 and REVEAL-2 phase 3 topline data.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260505135001) on May 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.